Hasinoff BB - Search Results

1

Hasinoff BB. Hasinoff BB. Semin Oncol. 1998 Aug;25(4 Suppl 10):3-9. Semin Oncol. 1998. PMID: 9768817

2

The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.

Hasinoff BB, Reinders FX, Clark V. Hasinoff BB, et al. Drug Metab Dispos. 1991 Jan-Feb;19(1):74-80. Drug Metab Dispos. 1991. PMID: 1673425

3

The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).

Hasinoff BB. Hasinoff BB. Drug Metab Dispos. 1990 May-Jun;18(3):344-9. Drug Metab Dispos. 1990. PMID: 1974197

4

Clinical and chemical interactions between iron preparations and ciprofloxacin.

Kara M, Hasinoff BB, McKay DW, Campbell NR. Kara M, et al. Among authors: hasinoff bb. Br J Clin Pharmacol. 1991 Mar;31(3):257-61. doi: 10.1111/j.1365-2125.1991.tb05526.x. Br J Clin Pharmacol. 1991. PMID: 2054264 Free PMC article. Clinical Trial.

5

The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).

Hasinoff BB. Hasinoff BB. Agents Actions. 1990 Mar;29(3-4):374-81. doi: 10.1007/BF01966470. Agents Actions. 1990. PMID: 2160191

6

The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.

Hasinoff BB. Hasinoff BB. Agents Actions. 1989 Mar;26(3-4):378-85. doi: 10.1007/BF01967305. Agents Actions. 1989. PMID: 2544086

7

A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).

Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM. Hasinoff BB, et al. Biochem Pharmacol. 1995 Sep 28;50(7):953-8. doi: 10.1016/0006-2952(95)00218-o. Biochem Pharmacol. 1995. PMID: 7575679

8

NADPH-cytochrome-P450 reductase promotes hydroxyl radical production by the iron complex of ADR-925, the hydrolysis product of ICRF-187 (dexrazoxane).

Hasinoff BB. Hasinoff BB. Free Radic Res. 1995 Apr;22(4):319-25. doi: 10.3109/10715769509145644. Free Radic Res. 1995. PMID: 7633562

9

Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system.

Malisza KL, Hasinoff BB. Malisza KL, et al. Among authors: hasinoff bb. Arch Biochem Biophys. 1995 Aug 1;321(1):51-60. doi: 10.1006/abbi.1995.1367. Arch Biochem Biophys. 1995. PMID: 7639535

10

Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.

Malisza KL, Hasinoff BB. Malisza KL, et al. Among authors: hasinoff bb. Arch Biochem Biophys. 1995 Feb 1;316(2):680-8. doi: 10.1006/abbi.1995.1091. Arch Biochem Biophys. 1995. PMID: 7864623

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results